HC Wainwright Rates Neumora Therapeutics (NMRA) buy

HC Wainwright maintains a buy rating for Neumora Therapeutics, setting a $7.00 price target, a 363.58% upside from the current price.

By EarningsIQ Research Desk · Published Jun 17, 2026, 2:02 AM EDT · Updated Jun 22, 2026, 1:02 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Neumora Therapeutics, Inc. ($NMRA) "buy" with a $7 price target on June 16, 2026.

Since the rating, $NMRA is up 3.2% after 1 week, up 2.6% after 1 month and down 69.9% to date (from the $1.56 close on Jun 16, 2026).

NMRA Neumora Therapeutics, Inc.

$0.47 -71.69% year to date

Daily close · Oct 16, 2026

Key Points

On June 16, 2026, HC Wainwright reiterated its buy rating for Neumora Therapeutics, Inc. (NMRA) with a price target of $7.00.
HC Wainwright's $7 price target implies 363.58% upside from Neumora Therapeutics, Inc.'s ($NMRA) current $1.51 share price.
Shares of NMRA are trading around $0.91, with a market cap of approximately $289 million and a 52-week range of $0.72 to $3.65.
Insiders including Fust Matthew and Ho Maykin recently bought shares, while analysts like Needham and Guggenheim have also set buy ratings.

Get $NMRA trade alerts by text

We text you when insiders, Congress or big funds trade $NMRA. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Neumora Therapeutics, Inc. alert may contain errors. Disclosures

On June 16, 2026, HC Wainwright reiterated its buy rating on Neumora Therapeutics, Inc. (NasdaqGS: NMRA), maintaining a price target of $7.00. This analysis comes as Neumora's shares are trading at around $0.91.

What Changed in HC Wainwright's Neumora Therapeutics Position

HC Wainwright's analyst Douglas Tsao continues to see potential in Neumora Therapeutics, maintaining a buy rating with a target price of $7.00. This suggests confidence in the company's future prospects, especially as it navigates its clinical trials.

Other Institutional Activity in Neumora Therapeutics

Several other institutional investors have also been active in Neumora Therapeutics. SIREN, L.L.C. increased its stake by 2,209,039 shares, bringing its total to 8,497,822 shares, valued at about $16.57 million. In contrast, SoftBank Group Corp. trimmed its holdings by 339,419 shares, ending with 6,090,301 shares worth approximately $11.88 million. Perceptive Advisors LLC initiated a new position with 5,104,097 shares valued at roughly $9.95 million. Meanwhile, Vanguard Capital Management LLC also started a new position, acquiring 3,891,893 shares valued at about $7.59 million.

Neumora Therapeutics, Inc. Stock Up 106.8%

Shares of Neumora Therapeutics (NasdaqGS: NMRA) are currently trading near $0.91. The company has a market capitalization of approximately $289 million and a beta of 2.759, indicating higher volatility compared to the market. The stock's 52-week range spans from $0.72 to $3.65, with a 50-day moving average of $1.95 and a 200-day moving average of $2.20. Neumora's current ratio stands at 5.10, with a quick ratio of 4.88, and a debt-to-equity ratio of 75.51.

12-month forecast

$NMRA price target

Neumora Therapeutics, Inc. daily closes and this analyst's $7 target. Not advice.

Recent Earnings

Neumora Therapeutics is not currently profitable, with a forward P/E ratio not meaningful due to negative earnings. Its latest earnings report showed an EPS of -$1.33. The company is expected to announce its next earnings on August 6, 2026.

Insider Buying and Selling at Neumora Therapeutics, Inc.

Recent insider activity at Neumora Therapeutics includes several purchases. On May 27, 2026, insiders including Fust Matthew, Ho Maykin, Kristina Burow, Alaa Halawa, and David Piacquad each acquired 80,000 shares. These transactions were not part of a planned trading strategy. Additionally, on February 17, 2026, CFO Michael Lee Milligan sold 1,436 shares at an average price of $3.57.

Analysts Set New Price Targets

On June 16, 2026, HC Wainwright & Co. maintained its buy rating with a $7.00 price target for Neumora Therapeutics. Similarly, Needham maintained a buy rating with a target of $5.00. The overall analyst consensus is a buy, with an average target price of $8.91 based on eight analyst opinions.

About Neumora Therapeutics

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases and neuropsychiatric disorders. Headquartered in Watertown, Massachusetts, and led by CEO Dr. Joshua Pinto, the company is advancing several candidates through clinical trials, including navacaprant for major depressive disorder and NMRA-511 for Alzheimer's-related agitation. Neumora aims to address unmet needs in neurodegenerative diseases with innovative therapies.

Bottom Line

HC Wainwright's reaffirmation of its buy rating for Neumora Therapeutics reflects ongoing confidence in the company's pipeline and market potential. As a clinical-stage biotech, Neumora is a subject of interest for investors tracking developments in brain disease treatments. Remember, analyst ratings are forward-looking assessments and may not reflect current market conditions.